Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)

Next Previous
X
Search
Trial Profile

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tirzepatide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms SURMOUNT-4
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 11 Dec 2023 Results presented in an Eli Lilly and Company media release.
    • 11 Dec 2023 Results (n=670) assessing the effect of tirzepatide, with diet and physical activity, on the maintenance of weight reduction, published in the JAMA: the Journal of the American Medical Association.
    • 27 Jul 2023 according to an Eli Lilly and Company Media Release , the full results of the SURMOUNT-4 study will be published at the European Association for the Study of Diabetes Annual Meeting in October and submitted for publication in a peer-reviewed journal.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top